Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Jun;25(6):906-8.
doi: 10.1038/leu.2011.29. Epub 2011 Feb 25.

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

K Detweiler Short  1 , S V Rajkumar, D Larson, F Buadi, S Hayman, A Dispenzieri, M Gertz, S Kumar, J Mikhael, V Roy, R A Kyle, M Q Lacy
Affiliations
Clinical Trial

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

K Detweiler Short et al. Leukemia. 2011 Jun.

Abstract

We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years following diagnosis of MM was 3%. The response of EMD to pomalidomide plus low-dose dexamethasone included two complete and two partial responses among the 13 patients (response rate, 31%). Overall survival measured from trial entry was significantly shorter for patients with treatment-emergent EMD compared with those who did not have EMD, (median 16 months versus not reached, P=0.002).

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall survival. Kaplan–Meier plots showing inferior survival from trial entry in patients with extramedullary plasmacytoma compared with patients without extramedullary disease. EMD, extramedullary disease.
See this image and copyright information in PMC

References

    1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–2972. - PMC - PubMed
    1. Madan S, Kumar S. Review: extramedullary disease in multiple myeloma. Clin Adv Hematol Oncol. 2009;7:802–804. - PubMed
    1. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2009;21:325–330. - PubMed
    1. Kyle RA, Gertz MA, Witzig TE, Lust J, Lacy M, Dispenzieri A, et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc. 2003;78:21–33. - PubMed
    1. Blade J, Perales M, Rosinol L, Tuset M, Montoto S, Esteve J, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas [see comment] Br J Haematol. 2001;113:422–424. - PubMed

Publication types